Clinical trialNCT03500159TerminatedPhase 2Interventional

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

SponsorAquinox Pharmaceuticals (Canada) Inc.Enrollment3Chronic Pelvic Pain SyndromeChronic Prostatitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, multi-center, double-blind, parallel-group study, enrolling approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week treatment with AQX-1125 (active drug) compared to placebo. The subjects will be randomized to receive orally once-daily either AQX-1125 (200 mg) or placebo in a 1:1 ratio across approximately 30 centers in North America (United States and Canada). The study will consist of a screening period of up to 3 weeks, a 12-week treatment period followed by a 4-week off drug safety follow-up period, and an ophthalmic safety follow-up call at 3 months and visit at 6 months post last dose, for a total study duration of about 41 weeks.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Shoskes, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Site 1005
Brampton, Ontario, Canada
Site 1025
Kingston, Ontario, Canada
Site 1003
Oakville, Ontario, Canada
Site 1024
Toronto, Ontario, Canada

United States

Site 1026
Homewood, Alabama, United States
Site 1010
Mobile, Alabama, United States
Site 1004
Tucson, Arizona, United States
Site 1028
Laguna Hills, California, United States
Site 1018
Los Alamitos, California, United States
Site 1016
Los Angeles, California, United States
Site 1020
Los Angeles, California, United States
Site 1027
New Port Richey, Florida, United States
Site 1013
Coeur d'Alene, Idaho, United States
Site 1015
Springfield, Illinois, United States
Site 1023
Jeffersonville, Indiana, United States
Site 1014
West Des Moines, Iowa, United States
Site 1012
Shreveport, Louisiana, United States
Site 1002
Royal Oak, Michigan, United States
Site 1011
Albuquerque, New Mexico, United States
Site 1009
Lake Success, New York, United States
Site 1021
Charlotte, North Carolina, United States
Site 1008
Raleigh, North Carolina, United States
Site 1019
Wilmington, North Carolina, United States
Site 1001
Cleveland, Ohio, United States
Site 1017
Oklahoma City, Oklahoma, United States
Site 1007
Philadelphia, Pennsylvania, United States
Site 1022
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AQX-1125 200 mgPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Apr 2018
Primary completion: 17 Jul 2018
Completion: 17 Jul 2018
Last update posted: 9 Jan 2019
Registered enrollment: 3
Registry id: NCT03500159

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.